FDA Grants Full Approval to Iptacopan for IgA Nephropathy

First Complement Inhibitor to Reach Full Approval

The U. S. Food and Drug Administration gave its final nod to iptacopan, sold as Fabhalta, on July 17 2026. The drug is intended to slow the loss of kidney function in adults with IgA nephropathy, a common form of glomerulonephritis. Approval follows a successful phase III trial that demonstrated a clear benefit over standard care.

IgA nephropathy, also known as Berger disease, is driven by immune complexes that deposit in the kidney’s filtering units. Existing therapies focus on blood‑pressure control and immunosuppression, but many patients still progress to end‑stage renal disease. Iptacopan blocks the alternative complement pathway, a key driver of inflammation in this condition. In the trial, participants receiving iptacopan experienced a markedly slower decline in estimated glomerular filtration rate (eGFR) compared with placebo, while safety signals remained low.

The study enrolled over 500 patients across North America and Europe. Researchers reported a 30 percent reduction in the annual eGFR decline for the iptacopan group. „These results represent a meaningful shift in disease trajectory,” said Dr. Laura Chen, lead investigator at the Nephrology Research Institute. Adverse events were comparable between treatment and control arms, with the most common issues being mild gastrointestinal upset. The FDA’s decision marks the first time a complement‑targeting agent has received full approval for a kidney disease, underscoring the growing confidence in pathway‑focused therapies.

Will Iptacopan Change the Standard of Care for IgA Nephropathy?

Clinicians anticipate that Fabhalta will become a cornerstone for patients at risk of rapid progression. Insurance providers are already reviewing coverage policies, and early access programs are being set up in several major hospitals. Experts caution that long‑term real‑world data will be needed to confirm durability of benefit, but the drug’s mechanism offers a clear advantage over broad immunosuppression. Ongoing studies aim to evaluate iptacopan in combination with existing antihypertensive regimens, potentially expanding its use to earlier disease stages.

If the drug delivers on its promise, thousands of individuals could avoid dialysis or transplantation, easing both personal and societal burdens. The approval also signals a broader shift toward precision medicine in nephrology, encouraging further development of targeted agents for other complement‑mediated disorders.

Frequently Asked Questions

What is iptacopan’s mechanism of action? Iptacopan inhibits factor B, a central component of the alternative complement pathway, reducing inflammatory damage in the kidney’s filtration structures.

Who is eligible for Fabhalta treatment? Adults diagnosed with IgA nephropathy who show evidence of progressive kidney function loss are candidates, pending physician assessment and insurance approval.

How soon will patients see benefits? Clinical trial data showed measurable slowing of eGFR decline within the first six months of therapy, with continued benefit observed over the study’s two‑year duration.